Management of Chronic Heart Failure in Children
For chronic heart failure in children with reduced ejection fraction, initiate triple therapy with an ACE inhibitor (captopril 0.5-1 mg/kg/day or enalapril), a beta-blocker (preferably β1-selective), and a mineralocorticoid receptor antagonist (spironolactone), while using loop diuretics as needed to maintain euvolemia 1, 2.
Initial Assessment and Stabilization
Determine the child's hemodynamic status by assessing:
- Perfusion status: Signs of low cardiac output (cool extremities, delayed capillary refill, metabolic acidosis, organ dysfunction)
- Volume status: Evidence of congestion (hepatomegaly, peripheral edema, pulmonary rales, elevated jugular venous pressure)
Critical pitfall: Do NOT give indiscriminate intravenous fluid resuscitation—this will worsen heart failure symptoms 1.
Pharmacologic Management Algorithm
Step 1: Achieve Euvolemia with Diuretics
Loop diuretics are the first-line therapy for congestion. Start furosemide at 0.5-1 mg/kg intravenously or orally every 6-12 hours 1. The goal is to return patients to euvolemia over days to weeks, then wean to the lowest effective dose. Monitor blood pressure, electrolytes, and renal function closely.
For diuretic resistance, add a thiazide agent (metolazone is most commonly used). This combination commonly causes hypokalemia and hyponatremia, requiring careful electrolyte monitoring 1.
Consider fluid restriction to 80% of basal metabolic requirements in some patients, balancing caloric needs 1.
Step 2: Initiate Neurohormonal Blockade (Cornerstone Therapy)
The foundation of chronic heart failure management targets maladaptive pathways to promote reverse remodeling 3, 2:
ACE Inhibitors (first-line neurohormonal blocker):
- Captopril, enalapril, or cilazapril are widely used in pediatrics 2, 4
- These reduce afterload, systemic vascular resistance, and ventricular pressures
- Tissue ACE inhibitors may confer additional benefits in children 2
- Monitor for hypotension, hyperkalemia, and renal dysfunction
Beta-blockers (essential component):
- β1-selective agents are preferred in children due to their mechanism of action 2
- Less commonly used in children than adults, but critical for reverse remodeling 4
- Start at low doses and titrate slowly to avoid decompensation
Mineralocorticoid receptor antagonists:
- Spironolactone is the third pillar of triple therapy 2
- Reduces fibrosis and improves outcomes
- Monitor potassium levels, especially when combined with ACE inhibitors
Step 3: Additional Conventional Therapies
Digoxin: Used more frequently in children than adults 2. Consider for symptomatic improvement and rate control, though evidence for mortality benefit is limited.
Angiotensin receptor blockers (ARBs): Alternative to ACE inhibitors if intolerance develops. Their slightly different mechanism may offer certain advantages 2.
Emerging Therapies (Based on Recent Evidence)
The 2024 ISHLT guidelines (not yet publicly available but discussed in recent literature) propose significant paradigm shifts 5:
Angiotensin receptor-neprilysin inhibitors (ARNIs): Now endorsed for pediatric HFrEF, showing potential for enhanced outcomes 5, 2.
SGLT2 inhibitors: Recommended for chronic HFrEF in children, representing a major advancement 5.
Soluble guanylate cyclase (sGC) stimulators: Endorsed for pediatric HFrEF management 5.
These novel therapies are already routine in adults and show promise for children, though pediatric-specific evidence remains limited 5.
Advanced Heart Failure Management
For patients unresponsive to medical therapy or requiring inotropic support:
Inotropic agents should be reserved only for the sickest patients with genuine low cardiac output, organ dysfunction, and metabolic acidosis 1. There is no long-term survival benefit, and toxicities limit their use. Key principles:
- Use only for bridging to mechanical circulatory support or transplantation
- If inotropic support exceeds 48 hours, develop a plan for weaning or transition to mechanical support
- Consider cardiac transplantation evaluation 1
Mechanical circulatory support and transplantation should be considered for end-stage heart failure refractory to medical management 6, 3.
Important Caveats
Evidence limitations: Almost all pediatric heart failure therapies are extrapolated from adult studies, as randomized controlled trials in children are sparse 6, 3, 5. The 2024 ISHLT guidelines acknowledge this with predominantly Level C (consensus-based) recommendations 5.
Pathophysiologic differences: Pediatric heart failure differs from adults at molecular and cellular levels, with less fibrosis and hypertrophy, potentially affecting treatment response 2. The pediatric myocardium has greater regenerative potential that should be optimized 2.
Monitoring requirements: Serial assessment requires multimodality imaging, laboratory evaluation, cardiac catheterization, and potentially sleep/exercise studies 6.